These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25692017)

  • 1. Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.
    Haroldsen PE; Garovoy MR; Musson DG; Zhou H; Tsuruda L; Hanson B; O'Neill CA
    Pharmacol Res Perspect; 2015 Feb; 3(1):e00099. PubMed ID: 25692017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function.
    Haroldsen PE; Sisic Z; Datt J; Musson DG; Ingenito G
    Clin Ther; 2017 Jul; 39(7):1360-1370. PubMed ID: 28641995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
    Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
    Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS.
    Shieh P; Sharma K; Kohrman B; Oh SJ
    J Clin Neuromuscul Dis; 2019 Mar; 20(3):111-119. PubMed ID: 30801481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
    Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
    Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic characterization of acetylator genotype-dependent and -independent N-acetyltransferase isozymes in homozygous rapid and slow acetylator inbred hamster liver cytosol.
    Trinidad A; Kirlin WG; Ogolla F; Andrews AF; Yerokun T; Ferguson RJ; Brady PK; Hein DW
    Drug Metab Dispos; 1989; 17(3):238-47. PubMed ID: 2568903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
    Thakkar N; Guptill JT; Aleš K; Jacobus D; Jacobus L; Peloquin C; Cohen-Wolkowiez M; Gonzalez D;
    CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):625-634. PubMed ID: 28623849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.
    Garcés-Eisele SJ; Cedillo-Carvallo B; Reyes-Núñez V; Estrada-Marín L; Vázquez-Pérez R; Juárez-Calderón M; Guzmán-García MO; Dueñas-González A; Ruiz-Argüelles A
    J Clin Pharm Ther; 2014 Aug; 39(4):368-75. PubMed ID: 24702251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
    Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
    Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
    Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
    Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism].
    Furet Y; Bechtel Y; Le Guellec C; Bechtel PR; Autret-Leca E; Paintaud G
    Therapie; 2002; 57(5):427-31. PubMed ID: 12611196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators.
    Antila S; Pesonen U; Lehtonen L; Tapanainen P; Nikkanen H; Vaahtera K; Scheinin H
    Eur J Pharm Sci; 2004 Nov; 23(3):213-22. PubMed ID: 15489122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow?
    O'Neil WM; Gilfix BM; DiGirolamo A; Tsoukas CM; Wainer IW
    Clin Pharmacol Ther; 1997 Sep; 62(3):261-71. PubMed ID: 9333101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity.
    Cribb AE; Isbrucker R; Levatte T; Tsui B; Gillespie CT; Renton KW
    Pharmacogenetics; 1994 Jun; 4(3):166-70. PubMed ID: 7920698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylator genotype-dependent expression of arylamine N-acetyltransferase in human colon cytosol from non-cancer and colorectal cancer patients.
    Kirlin WG; Ogolla F; Andrews AF; Trinidad A; Ferguson RJ; Yerokun T; Mpezo M; Hein DW
    Cancer Res; 1991 Jan; 51(2):549-55. PubMed ID: 1985773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the acetylator phenotype on amrinone pharmacokinetics.
    Hamilton RA; Kowalsky SF; Wright EM; Cernak P; Benziger DP; Stroshane RM; Edelson J
    Clin Pharmacol Ther; 1986 Dec; 40(6):615-9. PubMed ID: 3780123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphic expression of acetyl coenzyme A-dependent arylamine N-acetyltransferase and acetyl coenzyme A-dependent O-acetyltransferase-mediated activation of N-hydroxyarylamines by human bladder cytosol.
    Kirlin WG; Trinidad A; Yerokun T; Ogolla F; Ferguson RJ; Andrews AF; Brady PK; Hein DW
    Cancer Res; 1989 May; 49(9):2448-54. PubMed ID: 2784998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.